💊 Centessa Surges on $6.3B Eli Lilly Acquisition | Biotech Sector Insights
IBB rose over 4% as biotech rallied on renewed M&A momentum, led by Eli Lilly's agreement to acquire Centessa. Gains across holdings including Apellis, Regeneron, Moderna and Gilead supported the move, reflecting improved sentiment in the sector.
Welcome to the MarketReader Minute.
Below are AI-generated insights on moves in the health care/biotechnology sector, powered by MarketReader technology.
Tuesday, March 31
IBB [+4.1%]
iShares Biotechnology ETF
The iShares Biotechnology ETF (IBB) is currently benefiting from significant positive momentum in the biotech sector, which has seen a notable rise due to merger and acquisition activity, particularly Eli Lilly's agreement to acquire Centessa Pharmaceuticals for $5.6 billion. This development is likely contributing to IBB’s daily performance, which is trading higher. Key contributors to the ETF's performance include APLS, REGN, MRNA, GILD, and ALNY, with substantial returns from each. Additionally, the broader market sentiment is reflected in the performance of correlated assets, such as the iShares iBoxx $ High Yield Corporate Bond ETF (HYG), which has also increased. Overall, these factors are aligning to support IBB’s current upward movement.